Hormone therapy methods and hormone products for abating coronary artery blockage

• US 6,562,790 B2
• Filed: 02/05/2000
• Issued: 05/13/2003
• Est. Priority Date: 02/05/2000
• Status: Expired due to Fees

• Current Assignee: Edmund Y.M. Chein
• Original Assignee: Edmund Y.M. Chein
• Inventors: Chein, Edmund Y. M.
• Primary Examiner(s): Travers, Russell
• Assistant Examiner(s): Wang, Shengjun
• Application Number:
  US09/498,792
• Publication Number:
  US 20020065273A1
• Time in Patent Office: 1,193 Days
• Field of Search: 514/2, 514/21, 514/171, 514/177, 514/178, 514/182, 514/415, 514/12
• US Class Current: 514/8.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin

Abstract

Methods for abating coronary artery blockage in human subjects include administering a combination of natural hormones including human growth hormone with sufficient T3 thyroid supplement to maintain the body temperature of the subject at or above 97.6° F. upon awakening and at 98.7° F. or higher during afternoon hours. Testosterone, if any, administered to male subjects is in natural, gel form.

Claims

1. A method for abating coronary artery blockage in otherwise healthy male and female human subjects in need thereof comprising:

measuring hormone levels in a sample of the subject'"'"'s blood to determine that the level of human growth hormone and the supplemental hormones selected from the group consisting of sex hormone, melatonin hormone, adrenal hormone, thyroid hormone, and thymus hormone are below predetermined optimal physiological levels for an adult human;

replenishing said level of said deficient hormones to the predetermined optimal physiological levels, without maintaining said human subject'"'"'s body temperature upon awaking at or above about 97.6°

F., and without maintaining said subject'"'"'s body temperature in the range of about 98.7°

F. to about 99.0°

F. during afternoon hours;

with the additional step of administering to said human subject sufficient T3 thyroid supplement to maintain said human subject'"'"'s body temperature upon awaking at or above about 97.6°

F., and to maintain said subject'"'"'s body temperature in the range of about 98.7°

F. to about 99.0°

F. during afternoon hours; and

in the case of a male human subject whose natural testosterone level is below said predetermined physiological level, administering natural testosterone in gel form to effect said replenishing.

2. The method of claim 1 wherein the step of measuring the level of human growth hormone comprises measuring the level of insulin-like growth factor-I.

3. The method of claim 1 wherein the predetermined physiological level of human growth hormone is an insulin-like growth factor-I level of 350 μ

g./mL blood.

4. The method of claim 1, the step of replenishing said level of human growth hormone further comprising a regimen comprising subcutaneous injections of doses of less than 0.5 mg per day.

5. The method of claim 1 wherein said regimen of injections of human growth hormone are administered twice daily.

6. The method of claim 1, wherein said sex hormone comprises at least one of natural testosterone, progesterone, and estrogen.

7. The method of claim 1 wherein said adrenal hormone comprises dehydroepiandrosterone and pregnenolone.

8. The method of claim 1, in the step of measuring a sample of a human subject'"'"'s blood, further comprising determining whether each of the supplemental hormones are below predetermined physiological levels for an adult human.

9. The method of claim 8 wherein the predetermined physiological level per milliliter of blood of human growth hormone is an insulin-like growth factor-I level of 350 μ

g, the level of melatonin hormone is 18-69 μ

g, and the level of thyroid (T3) hormone is 150-180 μ

g.